MetaCap

SELLAS Life Sciences Group (SLS) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed Xencor (XNCR) over the past year, gaining 792.8% versus a gain of 109.6%. Over five years, SLS leads with a +94.0% price change compared with -6.2% for XNCR. SELLAS Life Sciences Group is the larger company by market cap ($2.78 billion vs $2.50 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLS+792.81%XNCR+109.58%
+1211%+559%-94%
Nov 21, 20251 yearNov 20, 2026
SLS+94.86%XNCR-9.77%
+131%+14%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLS versus XNCR key metrics
MetricSLSXNCR
Share price$13.66$33.26
Market cap$2.78B$2.50B
1-day change-8.08%-2.21%
YTD return+262.33%+117.24%
1-year return+792.81%+109.58%
5-year return+94.03%-6.15%
EPS (TTM)$-0.20$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$125.58M
Revenue growth (YoY)—+13.65%
Net income (latest FY)$-26.86M$-91.92M
Operating margin—-141.35%
Net margin—-73.20%
52-week high$24.89$40.60
52-week low$1.39$10.38
Distance from 52-week high-45.12%-18.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+137.92%+27.78%
Average volume9.64M1.54M
Shares outstanding203.86M75.04M
Employees13260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed XNCR by 683.2 percentage points over the past year.

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

SLS vs XNCR FAQ

Which is bigger, SELLAS Life Sciences Group or Xencor?

SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.78B compared with $2.50B for Xencor (XNCR).

Which stock has performed better over the past year, SLS or XNCR?

SLS returned +792.81% over the past 12 months, compared with +109.58% for XNCR (price return, excluding dividends). Past performance does not predict future results.

Are SELLAS Life Sciences Group and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons